earnings
confidence high
sentiment positive
materiality 0.75
OptimizeRx Q2 revenue $29.2M (+55% YoY); raises FY guidance to $104M-$108M
OptimizeRx Corp
2025-Q2 EPS
reported -$0.04
vs consensus $0.02
▼ miss
(-328.6%)
- Q2 GAAP net income $1.5M ($0.08/share) vs net loss of $4.0M ($0.22) YoY.
- Adjusted EBITDA $5.8M vs $0.5M YoY; non-GAAP net income $4.5M ($0.24 diluted).
- Q2 gross profit $18.6M, up 59% YoY; revenue growth driven by deeper pharma partnerships.
- Paid down $4.5M of principal on term loan during Q2, $4.0M above required schedule.
- FY 2025 guidance raised: revenue $104M-$108M, adjusted EBITDA $14.5M-$17.5M.